PT Kalbe Farma Tbk.
PTKFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.25 | -1.49 | 5.16 | 1.43 |
| FCF Yield | 5.01% | 2.37% | 2.36% | 2.42% |
| EV / EBITDA | 14.40 | 15.88 | 22.93 | 14.30 |
| Quality | ||||
| ROIC | 12.23% | 11.60% | 14.69% | 14.60% |
| Gross Margin | 39.71% | 37.94% | 40.45% | 42.97% |
| Cash Conversion Ratio | – | 1.05 | 1.11 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.09% | 5.06% | 7.77% | 5.08% |
| Free Cash Flow Growth | 104.50% | -40.38% | 58.86% | -41.06% |
| Safety | ||||
| Net Debt / EBITDA | -0.90 | -0.59 | -0.53 | -1.15 |
| Interest Coverage | 72.22 | 38.18 | 108.97 | 91.47 |
| Efficiency | ||||
| Inventory Turnover | 3.03 | 2.78 | 2.45 | 2.94 |
| Cash Conversion Cycle | 141.61 | 154.29 | 166.97 | 132.61 |